US Broker Ratings

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Challenges with a Strong Free Cash Flow

Avanos Medical, Inc. (NYSE: AVNS) operates within the healthcare sector, focusing specifically on medical devices. This Alpharetta, Georgia-based company has carved out a niche for itself by offering innovative medical..

Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Exploring a Potential 153.59% Upside

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is making waves in the biotech sector with its focus on pioneering treatments for rare diseases. With a market capitalization of $500.49 million, this Florida-based..

Autolus Therapeutics plc (AUTL): Unpacking the Potential 448% Upside for Investors

Autolus Therapeutics plc (NASDAQ: AUTL) has recently captured investor attention, not just for its innovative approach in the biotechnology sector but also due to its staggering potential upside of 448.17%...

Fortrea Holdings Inc. (FTRE) Stock Analysis: A Potential 49% Upside Beckons Investors

Fortrea Holdings Inc. (FTRE), a prominent player within the biotechnology sector, is capturing investor attention with its promising growth prospects and strategic collaborations. Based in Durham, North Carolina, Fortrea is..

SIGA Technologies Inc. (SIGA) Stock Analysis: Intriguing Valuation Metrics Amidst Revenue Challenges

SIGA Technologies Inc. (NASDAQ: SIGA), a key player in the healthcare sector specializing in drug manufacturing, presents a curious case for investors. With a market capitalization of approximately $484.81 million,..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Potential 91.59% Upside in the Biotechnology Sector

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a dynamic player in the biotechnology sector, has recently caught the attention of investors with a potential upside of 91.59%. The company, valued at..

Amylyx Pharmaceuticals (AMLX) Stock Analysis: A 50% Upside Opportunity in the Neurodegenerative Disease Market

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has been capturing the attention of investors with its potential to deliver significant upside, despite its current challenges. Operating within the fast-evolving healthcare sector, Amylyx..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Promising Biotech with a 325% Potential Upside

In the dynamic world of biotechnology, few companies present as intriguing a case for investors as LENZ Therapeutics, Inc. (NASDAQ: LENZ). With its focus on developing innovative therapies to improve..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Exploring a 40.76% Potential Upside in Pediatric Orthopedics

OrthoPediatrics Corp. (NASDAQ: KIDS), a specialized medical device company, is making waves in the healthcare sector with its unique focus on pediatric orthopedic solutions. With a market capitalization of $427.57..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech with a 9.78% Upside Potential

Maze Therapeutics, Inc. (NASDAQ: MAZE) represents a compelling opportunity within the biotechnology sector, particularly for those interested in pioneering healthcare innovations. With a market capitalization of $2.17 billion, Maze operates..

Simulations Plus, Inc. (SLP) Stock Analysis: Exploring a Potential 102% Upside Opportunity

Simulations Plus, Inc. (NASDAQ: SLP), a healthcare sector player specializing in health information services, is garnering attention with its potential 102% upside based on current analyst ratings. As a prominent..

RxSight, Inc. (RXST) Stock Analysis: A Closer Look at the 23.68% Potential Upside

RxSight, Inc. (RXST), a notable player in the healthcare sector, is making waves in the medical devices industry with its innovative approach to enhancing cataract surgery outcomes. Headquartered in Aliso..

Xencor, Inc. (XNCR) Stock Analysis: Exploring a Biotech Giant with 145% Upside Potential

Xencor, Inc. (NASDAQ: XNCR) is an intriguing player in the biotechnology sector, offering investors a significant upside potential of 145.60%, according to analyst ratings. With a market capitalization of $838.36..

Castle Biosciences, Inc. (CSTL) Stock Report: Analysts See 54.98% Potential Upside Amidst Innovative Diagnostics

Castle Biosciences, Inc. (NASDAQ: CSTL), a leader in molecular diagnostics, is making waves in the healthcare sector despite recent market fluctuations. With a market capitalization of $914.77 million, the company..

Stoke Therapeutics, Inc. (STOK) Stock Analysis: Impressive Revenue Growth and Promising Upside

Stoke Therapeutics, Inc. (NASDAQ: STOK), a prominent player in the biotechnology sector, has been catching the eyes of investors, boasting a market capitalization of $1.96 billion. This early-stage biopharmaceutical innovator..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a Potential 60.89% Upside in the Health Information Services Sector

HealthStream, Inc. (NASDAQ: HSTM), a stalwart in the Health Information Services industry, has been a focal point for investors eyeing the Healthcare sector. With its unique Software-as-a-Service (SaaS) offerings tailored..

Vir Biotechnology (VIR) Stock Analysis: A Potential 111% Upside Amidst Strategic Collaborations

Vir Biotechnology, Inc. (NASDAQ: VIR) presents a compelling case for investors with its ambitious pipeline in the fight against infectious diseases and a significant potential upside. With a market capitalization..

Inventiva S.A. (IVA) Stock Analysis: Biotech Breakthroughs with 131% Potential Upside

Inventiva S.A. (IVA), a France-based clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its focus on developing innovative treatments for metabolic and fibrotic diseases. As it stands,..

CureVac N.V. (CVAC) Stock Analysis: Navigating a Transformational Path in Biotechnology

CureVac N.V. (NASDAQ: CVAC), a pioneering entity in the biotechnology sector, has attracted attention with its innovative approach to messenger ribonucleic acid (mRNA) technology. Despite facing significant challenges, this German-based..

Immunome, Inc. (IMNM)

⚠️ No article content returned.

..
Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds